Fig. 2.From: Current and emerging therapies for primary central nervous system lymphomaTimeline of the development of targeted chemoimmunotherapy for PCNSL. WBRT and the CHOP-like regimen were the major methods used to treat PCNSL in the early 1970s, until high-dose MTX was established as the backbone for chemoimmunotherapy with ASCT or WBRT administered during consolidation. In the past 5 years, more targeted therapies, including rituximab, ibrutinib, and lenalidomide, have been applied to treat ND or r/r patients.Back to article page